MAIA Biotechnology (NYSEAMERICAN:MAIA) Director Buys $12,414.09 in Stock

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Director Ramiro Guerrero bought 8,931 shares of MAIA Biotechnology stock in a transaction dated Wednesday, August 26th. The shares were bought at an average cost of $1.39 per share, for a total transaction of $12,414.09. Following the completion of the transaction, the director owned 610,842 shares of the company’s stock, valued at approximately $849,070.38. This trade represents a 1.48% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Ramiro Guerrero also recently made the following trade(s):

• On Friday, August 28th, Ramiro Guerrero purchased 46,620 shares of MAIA Biotechnology stock. The stock was purchased at an average price of $1.35 per share, with a total value of $62,937.00.
• On Thursday, August 27th, Ramiro Guerrero purchased 78,239 shares of MAIA Biotechnology stock. The stock was purchased at an average price of $1.39 per share, with a total value of $108,752.21.
• On Monday, August 24th, Ramiro Guerrero acquired 1,794 shares of MAIA Biotechnology stock. The stock was purchased at an average cost of $1.33 per share, for a total transaction of $2,386.02.
• On Thursday, August 20th, Ramiro Guerrero acquired 11,899 shares of MAIA Biotechnology stock. The shares were purchased at an average price of $1.37 per share, for a total transaction of $16,301.63.

MAIA Biotechnology Stock Performance

NYSEAMERICAN MAIA traded down $0.01 on Tuesday, reaching $1.30. 312,335 shares of the stock traded hands, compared to its average volume of 791,682. The company has a fifty day moving average price of $1.37 and a 200-day moving average price of $1.44. The company has a market cap of $79.08 million, a price-to-earnings ratio of -2.10 and a beta of 0.24. MAIA Biotechnology, Inc. has a 12 month low of $0.87 and a 12 month high of $3.19.

MAIA Biotechnology (NYSEAMERICAN:MAIA) last issued its earnings results on Monday, August 10th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.02). As a group, research analysts anticipate that MAIA Biotechnology, Inc. will post -0.54 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in MAIA. Centric Wealth Management purchased a new position in MAIA Biotechnology during the 2nd quarter valued at about $1,107,000. Solas Capital Management LLC purchased a new stake in shares of MAIA Biotechnology in the 2nd quarter worth approximately $4,364,000. Cable Car Capital LP bought a new position in shares of MAIA Biotechnology during the second quarter valued at approximately $741,000. Corsair Capital Management L.P. bought a new position in shares of MAIA Biotechnology during the first quarter valued at approximately $140,000. Finally, Jane Street Group LLC purchased a new position in MAIA Biotechnology during the fourth quarter valued at approximately $120,000. 5.65% of the stock is currently owned by institutional investors.

About MAIA Biotechnology

MAIA Biotechnology, Inc is a clinical?stage biopharmaceutical company developing a proprietary platform for site?specific conjugation of monoclonal antibodies with diagnostic and therapeutic radioisotopes. By leveraging precision radiochemistry, the company aims to enhance the safety and efficacy profiles of antibody?based imaging agents and targeted radiotherapeutics. Its approach is designed to deliver high?contrast tumor visualization through PET imaging as well as focused cytotoxicity in oncology indications.

The company’s pipeline includes several antibody?radiotracer candidates optimized for the detection of distinct tumor biomarkers, with preclinical data showing favorable targeting specificity and improved pharmacokinetics compared to conventional methods.